NEW YORK (GenomeWeb News) – Becton Dickinson today said that the US Food and Drug Administration has cleared for marketing its BD ProbeTec Chlamydia trachomatis Qx and BD ProbeTec Neisseria gonorrhoeae Qx Amplified DNA Assays with samples collected during women's routine liquid-based Pap testing for cervical cancer screening.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.